iCell Gene Therapeutics is proud to announce the publication of our preclinical CD5CAR NK cell data in Leukemia, a leading hematology-oncology journal titled "Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor". We demonstrate the efficacy of using CD5-redirected CAR NK cells against various T-cell malignancies and disease subsets expressing CD5. Read more about it here.


Comments are closed.